Divi's Laboratories Limited appears to be a financially healthy company with strengths in profitability and growth. The company boasts high gross margins and profit margins, indicating efficient operations and pricing power. Its revenue and earnings growth rates are also impressive, suggesting a strong business momentum. However, the company's valuation looks stretched, with a trailing P/E of 79.78 and a forward P/E of 116.62, indicating that the market has high expectations. On the positive side, the company has a very low debt-to-equity ratio of 0.027, indicating a strong balance sheet.